國家衛生研究院 NHRI:Item 3990099045/4585
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 855154      在线人数 : 990
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/4585


    题名: Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer
    作者: Tsai, CM;Chiu, CH;Chou, TY;Li, LH;Hsiao, CY;Chen, M;Perng, RP;Tsai, SF
    贡献者: Division of Molecular and Genomic Medicine
    摘要: Background: It has been reported that mutations in epidermal growth factor receptor (EGFR) play a critical role in predicting tumor response in patients receiving gefitinib for non-small cell lung cancer (NSCLC). We investigated the associations of EGFR mutations to tumor response and survival in gefitinib-treated NSCLC patients. Methods: We examined EGFR gene mutations in exons 18, 19 and 21 by DNA sequencing in paraffin-embedded tumor tissues of NSCLC patients who have received gefitinib. The results were correlated with the clinical parameters. Results: Mutations in the tyrosine kinase domain of EGFR were found in 29 of 54 cases (53.7%). Of them, twelve cases had a deletion in exon 19 and seventeen cases had a substitution in exon 18 and/or 21. Mutation was an independent predictor for disease control (P< 0.001) and tumor response (P= 0.020); the positive predictive values were 93% and 75% and negative predictive values were 60% and 65%, respectively. Compared with patients whose tumor bearing non-mutant EGFR, patients with EGFR mutations showed better progression-free survival (median 7.9 m vs. 1.8 m, P< 0.001) and overall survival (median 12 m vs. 4.7 m, P= 0.029). Moreover, in the gefitinib responders, patients with mutations had a longer response duration than patients without mutations (median 9.1 m vs. 2.9 m, P= 0.033). It was unlikely that patients with EGFR mutations in different exons have variable response or survival to gefitinib treatment. Conclusions: EGFR mutations can be used as a predictive and prognostic indicator in patients receiving gefitinib for NSCLC.
    日期: 2005-06
    關聯: Journal of Clinical Oncology. 2005 Jun;23(16):Abstract number 641S.
    Link to: http://meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/7086
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0732-183X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000230326604201
    显示于类别:[蔡世峯] 會議論文/會議摘要

    文件中的档案:

    没有与此文件相关的档案.



    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈